Efficacy and tolerability of candesartan cilexetil in special patient groups

Blood Pressure, Supplement

Volumn 9, Issue 1, 2000, Pages 27-30

  Trenkwalder, P ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Candesartan cilexetil; Diabetes mellitus; Heart failure; Hypertension; Metabolic disorders; Pulmonary disease; Renal failure; Severe hypertension; Women

Indexed keywords

ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; CALCIUM ANTAGONIST; CANDESARTAN HEXETIL; DIURETIC AGENT; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN RECEPTOR; BENZIMIDAZOLE DERIVATIVE; BIPHENYL DERIVATIVE; TETRAZOLE DERIVATIVE;

AGED; ANTIHYPERTENSIVE ACTIVITY; ATHEROSCLEROSIS; CLINICAL TRIAL; CONFERENCE PAPER; DIABETES MELLITUS; DRUG EFFECT; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; GERIATRIC PATIENT; GLUCOSE TOLERANCE; HEART FAILURE; HEART LEFT VENTRICLE HYPERTROPHY; HEART VENTRICLE REMODELING; HUMAN; HYPERTENSION; KIDNEY DISEASE; MICROALBUMINURIA; PRIORITY JOURNAL; DRUG ANTAGONISM; HEART DISEASE; INSULIN RESISTANCE; KIDNEY FAILURE; PATHOPHYSIOLOGY; REVIEW;

ANTIHYPERTENSIVE AGENTS; BENZIMIDAZOLES; BIPHENYL COMPOUNDS; HEART DISEASES; HUMANS; HYPERTENSION; INSULIN RESISTANCE; KIDNEY FAILURE; RECEPTOR, ANGIOTENSIN, TYPE 1; RECEPTOR, ANGIOTENSIN, TYPE 2; RECEPTORS, ANGIOTENSIN; TETRAZOLES;

EID: 0034567407     PISSN: 08038023     EISSN: None     Source Type: Journal    
DOI: 10.1080/080370500439191     Document Type: Conference Paper

References (10)

1. The efficacy of candesartan, an angiotensin II type I receptor antagonist alone or in combination with amlodipine or in combination with amlodipine and hydrochlorothiazide in patients with moderate-to-severe essential hypertension
2. Antihypertensive treatment with candesartan cilexetil does not affect glucose homeostasis or serum lipid profile in patients with mild hypertension and type II diabetes
3. Effects of an angiotensin receptor antagonist and angiotensin converting enzyme inhibitor on insulin sensitivity in fructose-fed hypertensive rats and essential hypertensives
4. Candesartan cilexetil, a novel angiotensin II antagonist, reduces microalbuminuria in patients with type II diabetes mellitus and mild hypertension
5. Effects of angiotensin II receptor antagonist, TCV-116, on renal haemodynamics in essential hypertension
6. Renal haemodynamic effects of the angiotensin II receptor antagonist candesartan cilexetil in patients with impaired and normal renal function
7. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP)
8. Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension)
9. Effective dose range of candesartan cilexetil for systemic hypertension. Candesartan cilexetil study investigators
10. 1) receptor blockade in hypertensive women: Benefits of candesartan cilexetil versus enalapril and hydrochlorothiazide